Pharmaceuticals
SN BioScience Doses First Patient in Phase 1b/2 Clinical Trial of 'SNB-101'
SEONGNAM, South Korea, May 14, 2026 /PRNewswire/ -- SN BioScience Inc., a clinical-stage biotechnology company based in South Korea, announced today that it has initiated the first patient dosing in its global Phase 1b/2 clinical trial evaluating SNB-101 (API: SN-38), a nanoparticle anticancer ag...
2026-05-15 07:03
1240
POMDOCTOR LIMITED Announces Fiscal Year 2025 Financial Results
GUANGZHOU, China, May 14, 2026 /PRNewswire/ -- Pomdoctor Limited ("Pomdoctor" or the "Company") (NASDAQ: POM), a leading online medical services platform for chronic diseases in China, today announced its financial results for the fiscal year ended December 31, 2025. Mr. Zhenyang Shi, Chairman a...
2026-05-15 04:30
2004
Datar Cancer Genetics Receives Landmark US FDA Clearance for CellDx-Tissue, a Comprehensive Genomic Profiling Assay for Solid Tumors Using DNA + RNA
Clearance Recognises CellDx-Tissue's Dual-Analyte DNA and RNA Workflow Across 517 Cancer-Associated Genes, with ALK, RET and ROS1 Fusion Calls on RNA-Level Evidence NASHIK, India, May 14, 2026 /PRNewswire/ -- Datar Cancer Genetics (DCG), a global precision oncology company, today announced that ...
2026-05-14 23:58
2519
CHEPLAPHARM to Accelerate Global Supply Chain Digitalization with TraceLink MINT
The German pharmaceutical company unifies its digital partner network, laying the foundation for AI-driven supply chain orchestration BOSTON, May 14, 2026 /PRNewswire/ -- TraceLink, the world's largest Agentic Business Network, today announced that the German-based but globally active CHEPLAPHAR...
2026-05-14 22:00
2223
OnCusp Therapeutics Appoints Anthony Kim as Chief Financial Officer
PRINCETON, N.J., May 14, 2026 /PRNewswire/ -- OnCusp Therapeutics, Inc., a clinical-stage biopharmaceutical company developing differentiated oncology therapies designed to translate cutting-edge innovation into clinically meaningful outcomes for patients, today announced the appointment of Antho...
2026-05-14 21:00
1730
Yuyu Pharma's Mervyn's Petcare Launches Cat Dental Care Treat on Amazon, Marking First Overseas Pet Health Push
SEOUL, South Korea, May 14, 2026 /PRNewswire/ -- Mervyn's Petcare, the U.S.
subsidiary of Korea-based Yuyu Pharmaceutical (KRX: 000220), has launched its
first cat dental care nutritional supplement product, "Ari's Purrfect Dental
Bites
2026-05-14 21:00
3260
MEDIPOST's CARTISTEM® Meets All Primary and Secondary Endpoints in Japan Phase 3 Trial and Demonstrates Statistically Significant Efficacy Gains Versus Active Control
- Achieved statistical significance versus standard-of-care (SOC) control across all key efficacy endpoints in the 52-week study - Japan Phase 3 results strengthen CARTISTEM's® global commercial prospects, with Japan biologics license application (BLA) scheduled for 2H 2026 SEOUL, South Korea and...
2026-05-14 10:30
2320
METiS TechBio, the World's First Publicly Listed AI-Powered Drug Delivery Company, Debuts on the Hong Kong Stock Exchange, "The SpaceX of Pharmaceuticals" Ushers in a New Era of Biopharmaceuticals
HONG KONG, May 13, 2026 /PRNewswire/ -- METiS TechBio (7666.HK), a tech-bio company focused on AI-powered nanodelivery innovation, today successfully listed on the Hong Kong Stock Exchange (HKEX), becoming the world's first publicly listed AI-powered drug delivery company and the first AI-powered...
2026-05-14 10:09
2331
Piramal Pharma Solutions Unveils State-of-the-Art Payload-Linker Suite at its Riverview, Michigan Facility
* The Riverview facility provides comprehensive services for active pharmaceutical ingredients (APIs) and high potency APIs (HPAPIs), including specialized solutions for payload-linkers. * This cutting-edge suite will significantly enhance the company's ability to support global payload-linke...
2026-05-13 22:45
2801
New Nature Communications Publication Highlights Efsubaglutide Alfa's Effects on Glycaemia and β-Cell Function
HONG KONG, May 12, 2026 /PRNewswire/ -- A major new clinical study, SUPER 2, has been published in Nature Communications, reporting that Efsubaglutide Alfa, a long-actingGLP-1 receptor agonist, significantly improved glycaemic control in adults with type 2 diabetes inadequately controlled on metf...
2026-05-13 11:47
2522
WuXi Biologics Included in 2026 Dow Jones Best‑in‑Class World Index and Emerging Markets Index
SHANGHAI, May 12, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that, in recognition of its continued efforts and exceptional performance in advancing sustainability, the Company has been included i...
2026-05-13 11:33
2228
Innovent to Present Multiple Clinical and Preclinical Results of Mazdutide and Next-Generation Obesity & Metabolic Pipeline at the 2026 ADA Scientific Sessions
SAN FRANCISCO and SUZHOU, China, May 12, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune,...
2026-05-13 08:00
2529
Kelun-Biotech Receives Investigational New Drug Approval from CDE for SKB118, a PD-1 x VEGF Bispecific Antibody
CHENGDU, China, May 12, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that it has received a clinical trial notice from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) appro...
2026-05-13 08:00
2913
Porton Advanced and Dark Horse Consulting Group Announce Memorandum of Understanding Providing A Streamlined Path to Conducting IITs in China
CRANBURY, N.J. and SUZHOU, China, May 12, 2026 /PRNewswire/ -- Porton Advanced, a premier contract development and manufacturing organization (CDMO) specializing in Advanced Therapy Medicinal Products (ATMPs), and Dark Horse Consulting Group ("DHCG" or "the Group"), a leader in strategic and oper...
2026-05-12 23:00
3512
Isomorphic Labs secures $2.1 Billion funding to scale its AI drug design engine
Isomorphic Labs will use the funding to power its world-leading AI drug design engine, scale its business globally and progress its drug candidate pipeline. LONDON, May 12, 2026 /PRNewswire/ -- Isomorphic Labs, an AI-first drug design and development company, today announced it has raised $2.1 Bi...
2026-05-12 22:27
2629
Halia Therapeutics to Present Final Phase 2 Ofirnoflast Data in Lower-Risk MDS at EHA2026 and Announces Appointment of Han Myint, MD, FACP, as Chief Medical Officer
European Hematology Association (EHA) oral presentation to report 67% hematological improvement, durable transfusion independence, and no treatment-related serious adverse events in ESA-refractory lower-risk MDS Dr. Myint, a hematology leader and oncology drug-development executive, joins Halia ...
2026-05-12 20:39
2331
Insilico Medicine and Ribo Enter Strategic Collaboration Agreement: Leveraging AI Platform and Automated Lab for End-to-End Empowerment of RNA Interference and Oligonucleotide Therapeutics Development
SHANGHAI, May 12, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 03696.HK), a biotechnology company powered by generative artificial intelligence , today announced that the company has entered a strategic collaboration agreement with Suzhou Ribo Life Science Co., Ltd. ("Ribo", 06938.HK), a ...
2026-05-12 20:30
2608
Ribo Announces Strategic Collaboration with Insilico Medicine to Accelerate siRNA Drug Development Driven by AI
SUZHOU, China, May 12, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. ("Ribo", 06938.HK) announced that the Company has entered into a strategic collaboration agreement with Insilico Medicine ("Insilico", 03696.HK). Both parties will leverage their respective core strengths in siRNA drug...
2026-05-12 20:30
2701
New Data Show Gaps in Antiviral Pipeline Against High-Risk Viral Threats
Longitudinal analysis reveals clear gaps in global preparedness against emerging viral threats and future pandemics. CAMBRIDGE, Mass., May 12, 2026 /PRNewswire/ -- New global analysis of antiviral compounds released today has identified a critically thin pipeline of treatments in development tha...
2026-05-12 19:00
1696
GIP Moves from Supporting Role to Key Variable: BrightGene Bio-Medical's Phase III Results Signal Differentiation in Weight Loss Arena
SUZHOU, China, May 12, 2026 /PRNewswire/ -- As competition in the weight loss drug market progressively intensifies, the latest Phase III clinical data disclosed by BrightGene Bio-Medical (688166.SH) for BGM0504 has reignited market attention. Mean weight reduction of 19.3%, waist circumference ...
2026-05-12 14:08
2233
Week's Top Stories
Most Reposted
Tonik Becomes the First Standalone Digital Bank in the Philippines to Achieve Profitability
[Picked up by 297 media titles]
2026-05-12 10:15
Visa amps up the music as Official Payment Partner for the Asia leg of The Weeknd's 'After Hours Til Dawn' Stadium Tour
[Picked up by 293 media titles]
2026-05-11 16:20
Avnet and HKSTP Invite Global Startups to New AI Hardware Launchpad
[Picked up by 290 media titles]
2026-05-12 10:00Peach Blossoms Celebrates Three Massive Wins - Black Pearl Restaurant Guide 2026, Asia's 50 Best Restaurants 2026 Extended List and Tatler Best 20 Restaurants in Singapore 2026
[Picked up by 283 media titles]
2026-05-12 14:00
Amity's Singapore-Headquartered AI Research Center Wins Gold at Taiwan's 2026 Best AI Awards
[Picked up by 280 media titles]
2026-05-13 08:00
Most Read
Amadeus delivers solid Q1 2026 growth, and maintains commercial momentum
2026-05-08 18:30
8672
CL Workshop Group Limited Receives Nasdaq Notice of Bid Price Deficiency
2026-05-08 21:10
7512
Pony.ai Labor Day Holiday Robotaxi Paid Orders Surge More Than Sixfold
2026-05-08 20:00
7211
Noah Holdings' Olive Asset Management Inaugurates N+ Club in Tokyo
2026-05-08 15:10
7012
Sohu.com to Report First Quarter 2026 Financial Results on May 18, 2026
2026-05-08 13:00
6737